Sanofi added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to bolster preparedness for emergencies, including potential pandemics.
The facility, named Modulus, came up at investment of $800 million at Tuas Biomedical Park in the city-state, according to a statement. It can be adapted to manufacture up to four vaccines or biopharmaceuticals at the same time, and will be fully operational in mid-2026 and create 200 skilled jobs in Singapore.
Modulus can also be reconfigured within a few days to transform between technological platforms, a process which traditionally takes months or years, the company said. It can house the equivalent of 34 standardised production modules.
The modular factory enables the company to respond with urgency in the event of public health challenges, Brendan O’Callaghan, executive vice president of manufacturing and supply, said in the statement. Sanofi completed another such modular facility in France earlier this year.
The facility’s addition ties in with Singapore’s efforts to boost vaccine manufacturing capacity. During the Covid-19 pandemic, the island nation had signed advance purchase agreements with multiple parties, made early downpayments for most promising vaccine candidates, including with Moderna, Pfizer-BioNTech and Sinovac and had arranged with pharmaceutical firms to facilitate their clinical trials and drug development in Singapore.
Earlier this year, AstraZeneca said it plans to build a US$1.5 billion ($2.01 billion) manufacturing facility, which is scheduled to open in 2029 to make antibody-drug conjugates.
See also: SingPost in 'exclusive' talks over divestment of Australia assets
Novartis in March said it will spend US$256 million to add to its biopharmaceutical manufacturing site, just a few months after AbbVie unveiled a US$223 million expansion of an existing manufacturing site.
